Cardiovascular prevention in HIV patients: Results from a successful intervention program

Atherosclerosis

Volumn 204, Issue 1, 2009, Pages 229-232

  Lima, Enéas M O ^a   Gualandro, Danielle M ^a   Yu, Pai C ^a   Giuliano, Isabela de C B ^a   Marques, André C ^a   Calderaro, Daniela ^a   Caramelli, Bruno ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Atherosclerosis; HIV; Myocardial infarction; Prevention; Protease inhibitors

Indexed keywords

ANTILIPEMIC AGENT; ANTIRETROVIRUS AGENT; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROTEINASE INHIBITOR; TRIACYLGLYCEROL;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL EVALUATION; CONTROLLED STUDY; DIABETES MELLITUS; DIET; DYSLIPIDEMIA; EXERCISE; FEMALE; GROUPS BY AGE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; SMOKING; SMOKING CESSATION;

ADULT; AGED; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BLOOD PRESSURE; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; DIET; EXERCISE; FEMALE; HIV INFECTIONS; HUMANS; LIPIDS; MALE; MIDDLE AGED; PROGRAM EVALUATION; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; RISK REDUCTION BEHAVIOR; SMOKING CESSATION; TIME FACTORS; TREATMENT OUTCOME;

EID: 67349250118     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2008.08.017     Document Type: Article

References (12)

1. Grinspoon S., and Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med 352 (2005) 48-62
2. Grinspoon S.K., Grunfeld C., Kotler D.P., et al. State of the science conference. Initiative to decrease cardiovascular risk and increase quality of care for patients living with HIV/AIDS executive summary. Circulation 118 2 (2008) 198-210
3. Grover S.A., Lowensteyn I., Joseph L., et al. Cardiovascular health evaluation to improve compliance and knowledge among uninformed patients (CHECK-UP) study group Patient knowledge of coronary risk profile improves the effectiveness of dyslipidemia therapy: the CHECK-UP study: a randomized controlled trial. Arch Intern Med 167 21 (2007) 2296-2303
4. Wilson P.W., D'Agostino R.B., Levy D., et al. Prediction of coronary heart disease using risk factor categories. Circulation 97 18 (1998) 1837-1847
5. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001;285(19):2486-97.
6. Assmann G., Schulte H., and Cullen P. New and classical risk factors -the Münster heart study (PROCAM). Eur J Med Res 2 6 (1997) 237-242
7. IV Brazilian guideline for dyslipidemia and atherosclerosis prevention: Department of Atherosclerosis of Brazilian Society of Cardiology. Arq Bras Cardiol 2007;88(I 1):2-19.
8. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 2003;289(19):2560-72.
9. De Socio G.V.L., Parruti G., Quirino T., et al. Identifying HIV patients with an unfavorable cardiovascular risk profile in the clinical practice: results from the SIMONE study. J Infect 57 (2008) 33-40
10. Law M.G., Friis-Moller N., El-Sadr W.M., et al. The use of Framingham equation to predict myocardial infarctions in HIV-infected patients: comparison with observed events in the D:A:D Study. HIV Med 7 (2006) 218-230
11. D:A:D study group. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007;356:1723-35.
12. D:A:D study group. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet 2008;371(9622):1417--26.